-
First-Line Osimertinib May Up Survival in EGFR-Mutated NSCLC
drugs
December 26, 2019
For patients with previously untreated advanced non-small cell lung cancer (NSCLC) with an EGFR mutation, overall survival is longer for treatment with osimertinib rather than ...
-
Vaccitech Oncology Limited Enters Collaboration with Cancer Research UK to Fund a Phase I/IIa Clinical Trial as First-Line NSCLC Therapy
b3cnewswire
December 25, 2019
Vaccitech Ltd announced today that its strategic collaboration with the Ludwig Institute for Cancer Research (Ludwig), Vaccitech Oncology Limited (VOLT) ...
-
CRUK partners with Vaccitech on NSCLC immunotherapeutic vaccine
pharmaceutical-technology
December 19, 2019
Vaccitech has signed a partnership with Cancer Research UK (CRUK) to clinically advance VTP-600, the former’s immunotherapy vaccine candidate, for patients with non-small cell lung cancer (NSCLC).
-
Lilly Opens Randomized Trial in Treatment-Naïve RET Fusion-Positive NSCLC
americanpharmaceuticalreview
December 17, 2019
Eli Lilly and Company announced the opening of the LIBRETTO-431 clinical trial for selpercatinib, also known as LOXO-292 ...
-
FDA Approves atezolizumab with nab-paclitaxel, Carboplatin for Metastatic NSCLC
americanpharmaceuticalreview
December 09, 2019
The Food and Drug Administration (FDA) has approved atezolizumab (TECENTRIQ, Genentech Inc.) in combination with paclitaxel protein-bound and ...
-
Can Aspirin Help Tackle Some Cancers?
drugs
September 24, 2019
Low-dose aspirin may improve survival odds for patients battling head/neck and lung cancer, two new studies suggest.
-
Electronic Nose Analysis May Predict Response to Anti-PD-1 Therapy in NSCLC
drugs
September 19, 2019
For patients with non-small cell lung cancer (NSCLC), responders and nonresponders can be differentiated by a metal oxide semiconductor electronic nose (eNose) analysis of exhaled breath before starting ...
-
Metastatic NSCLC therapy, tepotinib, given Breakthrough Designation
europeanpharmaceuticalreview
September 12, 2019
Tepotinib, an investigational therapy for patients with metastatic non-small cell lung cancer has been given Breakthrough Therapy Designation.
-
China grants Tagrisso (osimertinib) marketing authorisation
europeanpharmaceuticalreview
September 06, 2019
Following positive clinical trials, the Tagrisso drug has been given marketing authorisation in China for treatment of NSCLC.
-
Imfinzi combination fails advanced lung cancer study
europeanpharmaceuticalreview
August 23, 2019
A late-stage clinical trial for Imfinzi and an experimental treatment has not extended the lives of patients with advanced non-small cell lung cancer.